Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the target of a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 7,564 shares, a decline of 84.4% from the July 15th total of 48,491 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 247,388 shares, the short-interest ratio is currently 0.0 days.
Shionogi & Co., Ltd. Unsponsored ADR Price Performance
Shares of OTCMKTS:SGIOY opened at $8.87 on Wednesday. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $7.65 and a 12 month high of $12.00. The stock has a market cap of $15.10 billion, a price-to-earnings ratio of 8.87, a PEG ratio of 3.49 and a beta of 0.08. The stock’s 50 day moving average price is $8.78 and its 200 day moving average price is $9.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.47% and a net margin of 46.67%.The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $970.69 million. Equities research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.79 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Stories
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
